The past week in medtech saw a major IPO and a grim reminder about the importance of cybersecurity. Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss the week’s “Newmarker’s Newsmakers” during our DeviceTalks Weekly podcast. Without further ado, here’s this week’s MassDevice Top Five: 5. […]
A hospital ransomware attack may have caused a death in Germany
State authorities in North Rhine-Westphalia are investigating whether a hospital ransomware attack resulted in negligent homicide, according to a report by the German public broadcaster DW. Media reports say this may be the first time that a hospital cyberattack has caused a death, even if it was indirectly. Düsseldorf University Clinic had to redirect a […]
Outset Medical IPO raises nearly $278M
Outset Medical (Nasdaq: OM) has brought in nearly $278 million from its IPO that closed today, two days after its shares started trading on the Nasdaq. The maker of the Tablo hemodialysis system raised$277.9 million before deducting underwriting discounts and commissions and offering expenses. The nearly 10.3 million OM shares sold at an initial offering […]
CoreMap gains $10.5M in Series A round
Burlington, Vt.-based startup CoreMap has secured $10.5 million in a Series A funding round led by Qure Ventures. Founded in 2016, CoreMap is taking aim at atrial fibrillation (AF) with technology designed to map complex arrhythmias inside the heart. The company’s patented system combines an electrode pair design in a high-density array configuration with algorithm-driven […]
Abbott launches glucose biosensor for athletes in Europe
Abbott (NYSE:ABT) announced today that it is introducing the Libre Sense glucose sport biosensor for measuring athletes’ glucose. The company touts the Libre Sense as the world’s first glucose sport biosensor, using Abbott’s FreeStyle Libre continuous glucose monitor (CGM) technology to become the first personal-use product that allows for use beyond diabetes, according to a news […]
BD has another Class I infusion device recall
The FDA issued another Class I recall designation for the BD Alaris from Becton Dickinson (NYSE:BDX), this time for potentially incorrect displays. Recalled products include the BD Alaris syringe module (model 8110) and BD Alaris PCA module (model 8120), and the BD Alaris syringe/PCA sizer sensor replacement kit (P/N 122786). Affected products related to the infusion […]
CVS to double drive-thru COVID-19 testing sites
CVS Health (NYSE:CVS) announced today that it plans to add more than 2,000 new COVID-19 drive-thru test sites at select locations around the U.S. Currently, CVS manages the largest number of independently run COVID-19 test sites in the country, according to a news release. It expects that the 2,000 new locations will just about double its […]
Quest lets consumers order COVID-19 tests online
Quest Diagnostics (NYSE:DGX) today announced that consumers will be able to order one of its COVID-19 diagnostics online and collect the specimen at home, without visiting a doctor’s office. QuestDirect Active Infection is also available by drive-through at more than 500 Walmart Neighborhood Market locations. Results are interpreted by a physician and provided digitally through the […]
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct […]
U.S. should have enough COVID-19 vaccine by Q3 2021, CDC head tells Senate panel
CDC director Dr. Robert Redfield told a Senate panel today that the federal government should have enough coronavirus vaccine for Americans to resume “regular life” by the third quarter of 2021, according to a report by CNBC. Redfield said vaccinations could begin November or December of 2020 and that it could take 6 to 9 months to […]
Advisory panel to vote on FDA approval of Neovasc Reducer
Nine years after it won the CE Mark in Europe, the Neovasc (NSDQ:NVCN) Reducer device, designed to treat refractory angina, is close to an FDA decision on premarket approval. The agency’s Circulatory Systems Devices Panel is scheduled to discuss the Reducer at a virtual meeting set for Oct. 27, the FDA announced today. In a […]
- 1
- 2
- 3
- …
- 266
- Next Page »
